JP2015507636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015507636A5 JP2015507636A5 JP2014550596A JP2014550596A JP2015507636A5 JP 2015507636 A5 JP2015507636 A5 JP 2015507636A5 JP 2014550596 A JP2014550596 A JP 2014550596A JP 2014550596 A JP2014550596 A JP 2014550596A JP 2015507636 A5 JP2015507636 A5 JP 2015507636A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkenylene
- alkylene
- alkynylene
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims 29
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 28
- 125000000623 heterocyclic group Chemical group 0.000 claims 28
- 125000001072 heteroaryl group Chemical group 0.000 claims 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000005275 alkylenearyl group Chemical group 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000002947 alkylene group Chemical group 0.000 claims 14
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims 14
- 125000004450 alkenylene group Chemical group 0.000 claims 12
- 125000004419 alkynylene group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- -1 alkylene R 10 Chemical compound 0.000 claims 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000007830 nerve conduction Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012900057A AU2012900057A0 (en) | 2012-01-06 | Methods of treatment or prophylaxis | |
| AU2012900057 | 2012-01-06 | ||
| PCT/AU2013/000003 WO2013102242A1 (en) | 2012-01-06 | 2013-01-04 | Heterocyclic compounds and methods for their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015507636A JP2015507636A (ja) | 2015-03-12 |
| JP2015507636A5 true JP2015507636A5 (https=) | 2016-01-28 |
| JP6232384B2 JP6232384B2 (ja) | 2017-11-15 |
Family
ID=48744930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014550596A Active JP6232384B2 (ja) | 2012-01-06 | 2013-01-04 | 複素環式化合物およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9624243B2 (https=) |
| EP (1) | EP2800738B1 (https=) |
| JP (1) | JP6232384B2 (https=) |
| CN (1) | CN107011229B (https=) |
| AU (1) | AU2013202982C1 (https=) |
| CA (1) | CA2860577C (https=) |
| ES (1) | ES2802251T3 (https=) |
| NZ (1) | NZ626973A (https=) |
| PL (1) | PL2800738T3 (https=) |
| PT (1) | PT2800738T (https=) |
| WO (1) | WO2013102242A1 (https=) |
| ZA (1) | ZA201405253B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| AU2013202982C1 (en) | 2012-01-06 | 2017-01-05 | Novartis Ag | Heterocyclic compounds and methods for their use |
| PL2807153T3 (pl) | 2012-01-25 | 2020-09-07 | Novartis Ag | Związki heterocykliczne i sposoby ich zastosowania |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| NZ630908A (en) | 2013-07-08 | 2017-08-25 | Novartis Ag | Heterocyclic compounds and methods of their use |
| ES2883289T3 (es) | 2013-12-20 | 2021-12-07 | Astex Therapeutics Ltd | Compuestos heterocíclicos bicíclicos y sus usos en terapia |
| CN105085358A (zh) * | 2014-05-07 | 2015-11-25 | 中国医学科学院药物研究所 | 4-取代吡咯烷甲酰基硫代吗啉类dpp-iv抑制剂 |
| CN107001337B (zh) * | 2015-01-13 | 2021-05-04 | 诺华股份有限公司 | 作为血管紧张素ii型拮抗剂的吡咯烷衍生物 |
| PL3268356T3 (pl) * | 2015-03-12 | 2022-01-24 | Novartis Ag | Związki heterocykliczne i sposoby ich stosowania |
| WO2019084395A1 (en) | 2017-10-27 | 2019-05-02 | University Of Virginia Patent Foundation | COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION |
| AU2019236882B2 (en) | 2018-03-23 | 2023-08-10 | Beijing Tide Pharmaceutical Co., Ltd. | Receptor inhibitor, pharmaceutical composition comprising same, and use thereof |
| WO2020223715A1 (en) * | 2019-05-02 | 2020-11-05 | University Of Virginia Patent Foundation | Substituted (piperidin-1-yl)aryl analogues for modulating avilactivity |
| CA3157279A1 (en) * | 2019-11-21 | 2021-05-27 | Paul Richard Sebahar | Trpv4 receptor ligands |
| WO2021165927A1 (en) * | 2020-02-21 | 2021-08-26 | Wockhardt Bio Ag | 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents |
| CN115894498A (zh) * | 2022-10-01 | 2023-04-04 | 海化生命(厦门)科技有限公司 | 一种潜在抗病毒药物中间体bl及其合成方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654034A (en) | 1969-04-21 | 1972-04-04 | Eastman Kodak Co | Apparatus for positioning strip ends in a splicing alignment |
| US3654304A (en) * | 1970-01-26 | 1972-04-04 | Robins Co Inc A H | Alkyl 1 1a 2 6b-tetrahydrocycloprop(b)indole 1-carboxylates and acids |
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| WO1995009859A1 (en) * | 1993-10-07 | 1995-04-13 | The Du Pont Merck Pharmaceutical Company | Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring |
| DK0746544T3 (da) * | 1994-02-22 | 1999-06-07 | Merrell Pharma Inc | Indolderivater til behandling af østrogenafhængige neoplasmer og sygdomme |
| JPH0892207A (ja) * | 1994-07-26 | 1996-04-09 | Sankyo Co Ltd | ピロリジン誘導体 |
| US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| AU716519B2 (en) * | 1995-06-30 | 2000-02-24 | Laboratoires Merck Sharp & Dohme - Chibret Snc | Method of treating renal disease using an ace inhibitor and an A II antagonist |
| MXPA04001253A (es) * | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| AU2003259131A1 (en) * | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| MXPA05002493A (es) | 2002-09-05 | 2005-05-27 | Neurosearch As | Derivados de diarilurea y su uso como bloqueadores del canal del cloro. |
| CN101123878A (zh) * | 2003-07-29 | 2008-02-13 | 信号研发控股有限责任公司 | 氨基酸前药 |
| PT1830869E (pt) | 2004-12-24 | 2013-08-22 | Spinifex Pharm Pty Ltd | Método de tratamento ou profilaxia |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| WO2007053406A1 (en) * | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinations of antihypertensive and cholesterol lowering agents |
| CA2646379C (en) | 2006-03-20 | 2014-12-23 | The University Of Queensland | Method of treatment or prophylaxis inflammatory pain |
| WO2009039069A1 (en) * | 2007-09-20 | 2009-03-26 | University Of Rochester | Method and compositions for treatment or prevention of inflammatory conditions |
| HUE025411T2 (en) * | 2008-03-04 | 2016-02-29 | Vernalis R&D Ltd | azetidine |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5756800B2 (ja) * | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| WO2011073376A1 (en) | 2009-12-18 | 2011-06-23 | Euroscreen S.A. | Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disordersas as agonists of g- protein coupled receptor 43 (gpr43) |
| US20110152233A1 (en) * | 2009-12-18 | 2011-06-23 | Henner Knust | Pyrrolidine compounds |
| US9095587B2 (en) | 2010-01-19 | 2015-08-04 | Spinifex Pharmaceuticals Pty Ltd | Methods and compositions for improved nerve conduction velocity |
| AU2013202982C1 (en) | 2012-01-06 | 2017-01-05 | Novartis Ag | Heterocyclic compounds and methods for their use |
| CA2861066C (en) * | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| PT2807171T (pt) | 2012-01-25 | 2020-11-03 | Novartis Ag | Compostos heterocíclicos e métodos para a sua utilização |
| PL2807153T3 (pl) | 2012-01-25 | 2020-09-07 | Novartis Ag | Związki heterocykliczne i sposoby ich zastosowania |
| NZ630908A (en) | 2013-07-08 | 2017-08-25 | Novartis Ag | Heterocyclic compounds and methods of their use |
-
2013
- 2013-01-04 AU AU2013202982A patent/AU2013202982C1/en active Active
- 2013-01-04 PL PL13733645T patent/PL2800738T3/pl unknown
- 2013-01-04 CA CA2860577A patent/CA2860577C/en active Active
- 2013-01-04 PT PT137336459T patent/PT2800738T/pt unknown
- 2013-01-04 EP EP13733645.9A patent/EP2800738B1/en active Active
- 2013-01-04 WO PCT/AU2013/000003 patent/WO2013102242A1/en not_active Ceased
- 2013-01-04 JP JP2014550596A patent/JP6232384B2/ja active Active
- 2013-01-04 NZ NZ626973A patent/NZ626973A/en unknown
- 2013-01-04 ES ES13733645T patent/ES2802251T3/es active Active
- 2013-01-04 US US14/370,737 patent/US9624243B2/en active Active
- 2013-01-04 CN CN201610930815.9A patent/CN107011229B/zh active Active
-
2014
- 2014-07-17 ZA ZA2014/05253A patent/ZA201405253B/en unknown
-
2017
- 2017-02-06 US US15/425,375 patent/US10370388B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015507636A5 (https=) | ||
| JP2013545785A5 (https=) | ||
| JP2017537949A5 (https=) | ||
| JP2003531103A5 (https=) | ||
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| JP2010536887A5 (https=) | ||
| JP2017523169A5 (https=) | ||
| JP2015505296A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| RU2012138580A (ru) | Производные пиримидина и их применение в лечении респираторных заболеваний, таких как copd | |
| JP2016500661A5 (https=) | ||
| JP2018526367A5 (https=) | ||
| JP2013537203A5 (https=) | ||
| JP2016518434A5 (https=) | ||
| JP2010511626A5 (https=) | ||
| RU2012138579A (ru) | Производные пиримидина и их применение в лечении респираторных заболеваний, таких как copd | |
| JP2013529196A5 (https=) | ||
| JP2015518004A5 (https=) | ||
| JP2015537020A5 (https=) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2021501756A5 (https=) | ||
| JP2012236838A5 (https=) | ||
| JP2015535832A5 (https=) | ||
| JP2014500295A5 (https=) | ||
| JP2010539110A5 (https=) |